Table 1 Baseline characteristics of patients
Mean ± SD or n (%) | Median (range interquartile) | |
|---|---|---|
Age at diagnosis (years) | 62.09 ± 12.80 | 63 (50, 76) |
Age at initiation of antifibrotic therapy | 63.72 ± 12.72 | |
Male | 8 (72.72) | |
Former smoker | 5 (45.45) | |
Never smoker | 6 (54.54) | |
Cryobiopsy | 9 (81.81) | |
Follow-up time (days) since diagnosis | 903 (381, 1489) | |
Follow-up time (days) since antifibrotic initiation | 333 (156, 421) | |
FVC% pred at baseline | 62.82 ± 22.30 | 52.7 (49, 77) |
DLCO% pred at baseline | 35.55 ± 10.74 | 34 (29, 37.1) |
TORVAN index (points) | 17.18 ± 5.13 | 19 (13, 21) |
HRCT features | ||
Reticulations | 7 (63.6) | |
Traction bronchiectasis | 8 (72.7) | |
Honeycombing | 2 (27.2) | |
Ground-glass | 7 (63.6) | |
Consolidations | 3 (27.2) | |
Mosaic attenuation | 2 (27.2) | |
Upper-mid lung predominance | 3 (27.2) | |
Lower lung predominance | 4 (36.3) | |
Prednisone | 11 (100) | |
Daily dosage (mg) | 16.81 ± 11.18 | |
Azathioprin | 5 (45.04) | |
Daily dosage (mg) | 150 | |
Methotrexate | 1 (9,09) | |
Weekly dosage (mg) | 7.5 | |
Cyclophosphamide | 1 (9.09) | |
Dosage i.v. per cycle (mg) | 1000 | |